Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1924 participants.

Also called NCT05893498

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose diagnostic
Phase
Not applicable
Enrolled
  • 1,924 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05893498
Other papers using this trial's data
  • Angiography-Derived Fractional Flow Reserve to Guide PCI The New England journal of medicine, 2026-07-02 DOI, PubMed 41910384

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Israel, Japan, Switzerland, United Kingdom (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05893498. Randomized; no masking; primary purpose diagnostic. Start 2023-06-21 (actual); primary completion 2026-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment
Acronym
ALL-RISE
Intervention (Device)
FFRangio
Intervention (Device)
FFR or NHPR
Lead sponsor
CathWorks Ltd. (class: industry)
Collaborator
Cardiovascular Research Foundation, New York (class: other)

Record details

Record id
cardio:ct-nct05893498
Content hash
e9d6cbed3a8b4c117b412069a5f5ea7560738d68bc59fc3bb40f3beeeae33a61